+

WO2009069680A1 - Composition médicinale pour traiter une tumeur du stroma gastro-intestinal (gist), et matériel et procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal - Google Patents

Composition médicinale pour traiter une tumeur du stroma gastro-intestinal (gist), et matériel et procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal Download PDF

Info

Publication number
WO2009069680A1
WO2009069680A1 PCT/JP2008/071495 JP2008071495W WO2009069680A1 WO 2009069680 A1 WO2009069680 A1 WO 2009069680A1 JP 2008071495 W JP2008071495 W JP 2008071495W WO 2009069680 A1 WO2009069680 A1 WO 2009069680A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastrointestinal stromal
stromal tumor
prognosis
estimating
kit
Prior art date
Application number
PCT/JP2008/071495
Other languages
English (en)
Japanese (ja)
Inventor
Tadashi Kondo
Setsuo Hirohashi
Akira Kawai
Kazutaka Kikuta
Original Assignee
Japan Health Sciences Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Sciences Foundation filed Critical Japan Health Sciences Foundation
Publication of WO2009069680A1 publication Critical patent/WO2009069680A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention vise à proposer un marqueur de tumeur par lequel des cas de pronostic défavorable peuvent être distingués de cas de pronostic favorable à un rapport de discrimination élevé parmi les cas de tumeur du stroma gastro-intestinal. A cet effet, l'invention propose une composition médicale pour traiter une tumeur du stroma gastro-intestinal d'un patient qui est défini sur la base de l'expression de DDX39 parmi des patients souffrant de tumeur du stroma gastro-intestinal, laquelle composition comporte, comme ingrédient actif, du 4-(4-méthylpipérazin-1-ylméthyl)-N-[4-méthyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phényl]benzamide représenté par la formule suivante (I) : [Formule chimique 1] (I) ou un sel acceptable du point de vue pharmaceutique de celui-ci ; et sur un matériel et un procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal.
PCT/JP2008/071495 2007-11-29 2008-11-27 Composition médicinale pour traiter une tumeur du stroma gastro-intestinal (gist), et matériel et procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal WO2009069680A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007308856A JP5428004B2 (ja) 2007-11-29 2007-11-29 消化管間質腫瘍を患う患者の予後を予測するためのキット
JP2007-308856 2007-11-29

Publications (1)

Publication Number Publication Date
WO2009069680A1 true WO2009069680A1 (fr) 2009-06-04

Family

ID=40678572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071495 WO2009069680A1 (fr) 2007-11-29 2008-11-27 Composition médicinale pour traiter une tumeur du stroma gastro-intestinal (gist), et matériel et procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal

Country Status (2)

Country Link
JP (1) JP5428004B2 (fr)
WO (1) WO2009069680A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057045A1 (fr) * 2012-10-10 2014-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de tumeurs stromales gastro-intestinales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043295A1 (fr) * 2005-09-22 2007-04-19 Daiichi Pharmaceutical Co., Ltd. Procédé d'identification de composés inhibant ddx39
JP2008100958A (ja) * 2006-10-20 2008-05-01 Japan Health Science Foundation 消化管間質腫瘍（ｇｉｓｔ）を処置するための医薬組成物、ならびに消化管間質腫瘍を患う患者の予後を予測するためのキットおよび方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043295A1 (fr) * 2005-09-22 2007-04-19 Daiichi Pharmaceutical Co., Ltd. Procédé d'identification de composés inhibant ddx39
JP2008100958A (ja) * 2006-10-20 2008-05-01 Japan Health Science Foundation 消化管間質腫瘍（ｇｉｓｔ）を処置するための医薬組成物、ならびに消化管間質腫瘍を患う患者の予後を予測するためのキットおよび方法

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ARIMOTO Y.: "Jutsugo Imatinib Mesylate Toyo ga Yuko de atta Fukumaku Hanshu o Tomonatta Akusei I gastrointestinal stromal tumor no 1 Rei", JAPANESE JOURNAL OF GASTROENTEROLOGICAL SURGERY, vol. 38, no. 6, 2005, pages 614 - 619 *
CHENG, S.H.: "Genomic prediction of locoregional recurrence after mastectomy in breast cancer", J CLIN ONCOL, vol. 24, no. 28, 2006, pages 4594 - 4602 *
GASHAW, I.: "Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4", CELL MOL LIFE SCI, vol. 62, no. 19-20, 2005, pages 2359 - 2368 *
HIROTA S.: "Shokakan no Nenmakuka Shuyo 2004 Topics 2. Tyrosine Kinase Sogaizai ni yoru GIST no Chiryo Tekio", STOMACH AND INTESTINE, vol. 39, no. 4, 2004, pages 683 - 687 *
KIKUCHI, H.: "Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: Sequential analyses", CANCER SCI, vol. 97, no. 2, 2006, pages 127 - 132 *
MIMURA T.: "Shitteokitaikoto A La Carte GIST", MED PRACT, vol. 24, no. 3, 1 March 2007 (2007-03-01), pages 574 - 576 *
OKAMOTO, K.: "A Treatment Using STI571 for Jejunal Gastrointestinal Stromal Tumor (GIST) Accompanied with Liver Metastasis and Peritoneal Dissemination", INTERN MED, vol. 43, no. 12, 2004, pages 1151 - 1156 *
PARK, J.T.: "Notch3 gene amplification in ovarian cancer", CANCER RES, vol. 66, no. 12, 2006, pages 6312 - 6318 *
SUDO H.: "Toin ni Okeru I GIST Shujutsu Shorei no Kento", JAPANESE JOURNAL OF GASTROENTEROLOGICAL SURGERY, vol. 38, no. 7, 2005, pages 985 *
SUGIURA, T.: "Intracellular characterization of DDX39, a novel growth-associated RNA helicase", EXP CELL RES, vol. 313, no. 4, February 2007 (2007-02-01), pages 782 - 790 *
TAKAHASHI, T.: "An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors", INT J CLIN ONCOL, vol. 12, no. 5, October 2007 (2007-10-01), pages 369 - 374 *
TAKENAKA H.: "Imatinib Mesylate Toyo ga Soko shita I GIST Dojisei Kan Tahatsu Ten'i no 1 Rei", YAMAGUCHI MEDICAL JOURNAL, vol. 55, no. 5, 2006, pages 173 - 178 *
TAKITA, J.: "Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma", GENES CHROMOSOMES CANCER, vol. 40, no. 2, 2004, pages 120 - 132 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057045A1 (fr) * 2012-10-10 2014-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de tumeurs stromales gastro-intestinales

Also Published As

Publication number Publication date
JP2009132636A (ja) 2009-06-18
JP5428004B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
WO2002034727A3 (fr) Traitement de tumeurs stromales gastro-intestinales
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2005075425A3 (fr) Derives de bisaryluree
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
MXPA06001838A (es) Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
MY151295A (en) Pyrimidyl indoline compound
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
NZ596154A (en) Cyclic compound having substituted phenyl group
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
NO20080033L (no) Kinolinderivater som NK3-antagonister
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08853644

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载